Human papillomavirus 56 (HPV56) is a high-risk type of Alphapapillomavirus with a circular double-stranded DNA genome. It infects mucosal epithelium in the anogenital region, replicating in stratified squamous cells. Although less common than HPV16 and HPV18, persistent HPV56 infection has been associated with carcinogenesis.
Virology & Oncogenic Mechanisms
HPV56 is one of the high‑risk human papillomavirus types recognised by cancer agencies. Its genome encodes early proteins that co‑opt host replication machinery and regulate the cell cycle and late structural proteins forming the viral capsid. The E6 and E7 oncoproteins bind and degrade tumour suppressor proteins p53 and retinoblastoma, thereby promoting cell proliferation and inhibiting apoptosis. The virus attaches to heparan sulfate proteoglycans on keratinocytes and enters basal cells through microabrasions. Viral DNA is maintained as an episome and replicates in synchrony with epithelial differentiation; integration of the genome and constitutive expression of E6/E7 occur in malignant lesions. While HPV16 and HPV18 cause the majority of cervical cancers, high‑risk types including 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 also contribute to the disease burden.
Clinical Impact and Prevention
HPV56 has been detected in high‑grade squamous intraepithelial lesions and a small proportion of invasive cervical cancers. Its prevalence is generally low, but co‑infection with other high‑risk types may increase oncogenic potential. Current prophylactic vaccines do not include HPV56, so prevention relies on reducing transmission and early detection. Regular cervical screening with Pap tests and high‑risk HPV DNA testing allows identification of women infected with HPV56 and guides management of precancerous lesions. Most HPV56 infections are transient and cleared by the immune system, but persistence is more likely in smokers and individuals with weakened immunity. Barrier contraception, limiting the number of sexual partners, and smoking cessation reduce the risk of persistent infection. HPV56 is a high‑risk papillomavirus whose persistent infection can contribute to cervical carcinogenesis. Continued screening and risk reduction are important because this type is not covered by current vaccines. Related Terms: HPV33, HPV52, High‑risk HPV, E7 protein, Cervical screening